IGFBP2 and neoplasm: Separately, it has been observed that CAFs can suppress the insulin‐like growth factor‐1 receptor (IGF‐1R) signaling through their distinct secretome, particularly via abundant IGFBP2, thereby sensitizing resistant tumor cells to conventional antitumor agents [68].